; (II) chemical and other environmental pollution; (III) excessive energy consumption; (IV) negative externalities relating to waste; and (V) any other environmental or climate impacts the Council determines relevant; (ii) labor conditions for workers in the United States and globally who produce medical and pharmaceutical products consumed by individuals residing in the United States, including the degree to which such workers— (I) are ensured a protected right to organize; (II) are provided adequate workplace safety protections; and (III) are adequately compensated; (iii) efficiency and resiliency of processes under medical supply chains, including the ability of medical supply chains to adapt to sudden shifts in demand, including shifts in demand within discrete geographic regions; (iv) the reliance of the United States on international supply chains for medical products, including information about which types of medical products are primarily manufactured outside of the United States, and where such products are manufactured; and (v) human rights abuses in manufacturing of medical and pharmaceutical products and sourcing of those products, including abuses of indigenous rights and traditions. (B) Report On completion of the assessment conducted under subparagraph (A), the Council shall submit to Congress and make publicly available a report, to be known as the Green Health Care Manufacturing Report , that describes the findings of the assessment. (2) Recommendations (A) In general Based on the findings of the assessment conducted under paragraph (1)(A), the Council shall develop recommendations for regulations that would support a medical supply chain that is— (i) sustainable; (ii) free of greenhouse gas emissions; and (iii) based in the United States. (B) Inclusions The proposed regulations under subparagraph (A) shall— (i) support good labor conditions, worker protections, and employee rights to organize and collectively bargain